Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Denali Therapeutics IncDNLI | $19.74 | Strong Buy | $42.00 | +112.82% | 21 hours ago | |
Analyst RankingTop 22% #1155 out of 5229 analysts Average Return+0.98% Win Rate49%178 out of 363 Risk vs RewardPoor Good Analyst ColorMorgan Stanley's Matthew Harrison raised their price target on Denali Therapeutics (NASDAQ: DNLI) by 5% from $40 to $42 on 2026/03/26. The analyst maintained their Strong Buy rating on the stock. Harrison attributed their price target hike on Denali Therapeutics to the FDA's accelerated approval of its treatment for Hunter syndrome ahead of its 2026/04/05 PDUFA deadline. The analyst opined that the approval is "the start of a paradigm shift in treatment of MPS II/III and other lysosomal storage disorders." | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.